Cipla Health reinforces importance of Self-Care This Season Through Its Range of Wellness Products
MUMBAI, India, July 1, 2025 /PRNewswire/ -- Common flu, seasonal throat infections, and fevers are on the rise in India, making it imperative to practice every day self-care and community protection. Leading the charge, Cipla Health Ltd., one of India's most trusted fast-moving wellness goods (FMWG) companies, through its thoughtful and medically backed range of products, offers holistic support to navigate the ongoing seasonal challenges that have also seen a resurgence in respiratory illnesses like COVID-19.
Cipla Health's house of brands, including Cofsils, Cipladine, Prolyte ORS, Paracip, and Maxirich offers reliable solutions for Indian households to better manage these symptoms and maintain wellness.
Cofsils Lozenges offer fast relief from sore throat pain—starting in just 5 minutes. With a triple-action formula that fights viruses, bacteria and soothing effects, they're a handy companion when you're out and about.
Cipladine Gargles target throat infections right at the source. With povidone-iodine, a trusted ingredient for throat hygiene, it soothes symptoms like sore throat and tonsillitis and helps reduce the spread of viruses. It's also effective for on-demand oral care during seasonal illness.
Prolyte ORS is the go-to rehydration solution when one is feeling drained from fever or illness. Its WHO-recommended formula helps restore lost fluids and electrolytes, so they can bounce back quicker and stay balanced.
Paracip is Cipla Health's reliable paracetamol that helps ease common seasonal discomforts like body aches, headaches, and chills
Maxirich Daily Multivitamin helps keeping the energy up and immunity strong. Packed with over 13 essential vitamins and minerals, it supports everyone's daily health needs.
Commenting on this, Mr. Shivam Puri, MD & CEO, Cipla Health Limited, said, "At Cipla Health, our focus is to bring dependable preventive wellness solutions to every Indian household. With the weather shifting and instances of seasonal flu, respiratory illnesses on the rise, it is imperative to have access to simple yet effective care solutions. Our product portfolio has been thoughtfully designed to support families in staying prepared and protected."
By offering solutions rooted in science, Cipla Health continues to fulfil its mission of making wellness accessible, proactive, and holistic for all. Whether it's the common seasonal flu or an unseen viral wave, being prepared with the right care tools can go a long way in staying safe.
About Cipla Health Limited:
Cipla Health Limited, the fast-moving wellness goods (FMWG) arm of Cipla, was incorporated in 2015 with a vision to spearhead the wellness wave in India. Cipla Health has delivered rapid growth and today plays across a diverse portfolio of 20 brands with most key brands being No. 1 or No. 2 in their respective categories. The portfolio includes products in Pain Care (Omnigel), Smoking Cessation (Nicotex), Oral Rehydration Solutions (Prolyte), Medicated Ointments (Cipladine), Cough & Cold (Cofsils and Naselin), Multi Vitamins (Maxirich), Weight Gain (Endura Mass) and Personal Care (Rivela Dermascience, Cetafresh, Tugain Essentials).
Logo: https://mma.prnewswire.com/media/2658055/5252537/Cipla_Health_Logo.jpg
View original content:https://www.prnewswire.com/in/news-releases/cipla-health-reinforces-importance-of-self-care-this-season-through-its-range-of-wellness-products-302495467.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Honduras mandates face masks again as respiratory illnesses spike
Honduras mandates face masks again as respiratory illnesses spike TEGUCIGALPA (Reuters) -Over five years after the COVID-19 outbreak, Honduras has reinstated mandatory mask wearing in public spaces amid a spike in respiratory illnesses and as a variant of the virus spreads through the Central American country. Honduras' health ministry confirmed two deaths from the virus this week, among patients with underlying health conditions, bringing the country's total in 2025 to six. "We have already surpassed last year's infection limit; there are currently five people admitted to Hospital Escuela with suspected COVID-19," said the head of Health Surveillance, Lorenzo Pavon. Official data showed that from January to July last year, 596 COVID-19 cases were reported, while this year 654 cases have been recorded in the same period. The temporary measures, which took effect on Thursday, make masks obligatory in hospitals, airports, shopping centers, banks, schools, public transport, and other enclosed or crowded spaces. The government also ordered temporary work-from-home for state institutions. Authorities are urging the public to complete their COVID-19 and influenza vaccination schedules and to seek medical advice for respiratory symptoms. Frequent hand washing and the use of antibacterial gel continue to be recommended measures. Officials also warned that they will maintain monitoring of variants and will reinforce public information campaigns. The Ministry of Health reiterated that it will continuously evaluate the epidemiological situation and warned that the measures could be expanded if the number of infections continues to rise. Solve the daily Crossword
Medscape
2 hours ago
- Medscape
Wellness in 2 Minutes: Micro-Habits for Busy Docs
This transcript has been edited for clarity. Wellness does not have to mean an hour at the gym. Let's talk about quick micro-habits you can do in under 2 minutes on a shift. First, box breathing. Inhale for four, hold for four, exhale for four, hold for four. That's a tongue twister. Focusing on your breathing for a little while really helps calm your nervous system. Second, stretch your shoulders and neck, especially if you've been hunched over a computer writing your notes or you have been running nonstop. Third, pause and drink a glass of water. When's the last time you actually hydrated yourself? Fourth, step outside for some fresh air. Spending 30 seconds in the sunlight can really help reset your mood, especially if you're working in a room with no windows. Finally, write down one thing you did well that day. This really helps build confidence and a positive perspective. These tiny resets can really add up, and they're pretty realistic, even on a busy day.
Yahoo
4 hours ago
- Yahoo
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision CAMBRIDGE, MA / / July 25, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for an updated formulation of the COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. Following the CHMP's positive opinion, the European Commission will make a marketing authorization decision on Moderna's updated COVID-19 vaccine for the 2025-2026 season. "The CHMP's positive opinion on our updated COVID-19 vaccine targeting the SARS-CoV-2 variant LP.8.1 is an important milestone in our ongoing effort to protect people across the European Union," said Stéphane Bancel, Chief Executive Officer of Moderna. "COVID-19 continues to place a significant burden on vulnerable populations and healthcare systems. Updated vaccines can be an important tool for protecting individuals and societies." The CHMP decision is based on a combination of manufacturing and preclinical data, as well as previous clinical, non-clinical and real-world evidence supporting the efficacy and safety of Moderna's COVID-19 vaccines. The updated vaccine composition aligns with guidance from various global health authorities, which have identified the LP.8.1 strain as an appropriate update to the COVID-19 vaccine composition for the 2025-2026 vaccination season. Additional regulatory applications for Moderna's updated COVID-19 vaccines targeting LP.8.1 are under review around the world. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential authorization by the European Commission of Moderna's COVID-19 vaccine targeting the SARS-CoV-2 variant LP.8.1; and the opportunity for Moderna to sell COVID-19 vaccines to up to 17 participating European Union countries over a four-year period. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media:Clothilde CailletDirector, Country and Europe Communications Investors:Lavina TalukdarSenior Vice President & Head of Investor Relations+1 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
